The journey from gene knockout to clinical medicine: telotristat and sotagliflozin
Open Access
- 1 March 2019
- journal article
- review article
- Published by Taylor & Francis Ltd in Drug Design, Development and Therapy
- Vol. ume 13, 817-824
- https://doi.org/10.2147/dddt.s144556
Abstract
Gene knockout has been a powerful technique to evaluate the physiologic role of selected gene products. Lexicon pioneered high-throughput gene knockout technology and went further in designing agents to inhibit products of gene expression. Two agents have entered late-stage development. Telotristat is an inhibitor of tryptophan hydroxylase (TPH), preventing the production of serotonin. Although this agent blocks the two isoforms of TPH, it does not cross the blood–brain barrier, thus avoiding central neurologic manifestations. It inhibits the peripheral production of serotonin, and in particular prevents serotonin action in the intestines, resulting in decreased peristaltic action. Lexicon successfully developed telotristat to treat carcinoid syndrome not responding adequately to somatostatin inhibitors. Sotagliflozin development proceeded from the observation that dual inhibition of SGLT2 in the kidneys and SGLT1 in the intestines resulted in increased renal glucose excretion, reduced early-phase glucose absorption, as well as increased blood levels of GLP-1 and PYY. Initial development efforts focused on type 1 diabetes and have shown reduced postprandial glucose levels, less tendency to hypoglycemia, and lower HbA1c. Several other SGLT2 inhibitors have been associated with increased frequency of diabetic ketoacidosis (DKA). In the type 1 trials, sotagliflozin-treated individuals experienced DKA at a higher rate than placebo-treated patients. The sotagliflozin development program has now been extended to trials on type 2 diabetes. Long-term clinical trials will determine the benefits and risks of the agent in comparison to other currently marketed SGLT2 inhibitors.Keywords
This publication has 49 references indexed in Scilit:
- Evolving Treatment Strategies for Management of Carcinoid TumorsCurrent Treatment Options in Oncology, 2013
- LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled TrialClinical Pharmacology & Therapeutics, 2012
- Essential Roles of Enteric Neuronal Serotonin in Gastrointestinal Motility and the Development/Survival of Enteric Dopaminergic NeuronsJournal of Neuroscience, 2011
- Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family membersDiabetes Therapy, 2010
- Novel l-Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Treatment of Type 2 DiabetesJournal of Medicinal Chemistry, 2009
- Genetic Disruption of Both Tryptophan Hydroxylase Genes Dramatically Reduces Serotonin and Affects Behavior in Models Sensitive to AntidepressantsPLOS ONE, 2008
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first centuryNature Reviews Genetics, 2005
- Different properties of the central and peripheral forms of human tryptophan hydroxylaseJournal of Neurochemistry, 2004
- Synthesis of Serotonin by a Second Tryptophan Hydroxylase IsoformScience, 2003